Palabras clave
Dolor crónico
Marihuana medicinal
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Analizar la evidencia disponible en la literatura científica sobre los efectos del cannabidiol (CBD) en la reducción del dolor y la mejora de la calidad de vida de pacientes adultos con dolor crónico. Métodos: Se realizó una revisión bibliográfica integradora a través de las bases de datos PubMed, Biblioteca Virtual en Salud (BVS) y CAPES Periodicals, utilizando los descriptores: "Cannabidiol", "Dolor Crónico" y "Adultos", y obteniendo el truncamiento de búsqueda: (Cannabidiol) AND (Dolor Crónico) AND (Adultos). Se encontraron 343 artículos, filtrados según los criterios de inclusión (portugués, inglés y español; publicados entre 2020 y 2025; artículos completos) y de exclusión (artículos duplicados, resúmenes, artículos fuera del alcance). Resultados: El cannabidiol (CBD) es un compuesto derivado del cannabis que se ha estudiado como tratamiento terapéutico alternativo para el dolor crónico en adultos, mostrando efectos analgésicos, mejor calidad de vida y una posible reducción del consumo de opioides. Consideraciones finales: El cannabidiol (CBD) ha demostrado efectos positivos en el manejo del dolor crónico en adultos, con un menor consumo de opioides y una baja incidencia de efectos adversos, aunque aún se necesitan estudios más sólidos para confirmar su eficacia y seguridad.
Referencias
ABRAMS DI, et al. Effect of inhaled cannabis for pain in adults with sickle cell disease: A randomized clinical trial: A randomized clinical trial. JAMA network open, 2020; 3(7): e2010874.
ARAGONA F, et al. Role of cannabidiolic acid or the combination of cannabigerol/cannabidiol in pain modulation and welfare improvement in horses with chronic osteoarthritis. Frontiers in veterinary science, 2024; 11: e1496473.
BAWA Z, et al. An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Scientific reports, 2024; 14(1): 11792.
BERGMANS RS, et al. Protocol for a pragmatic trial of Cannabidiol (CBD) to improve chronic pain symptoms among United States Veterans. BMC complementary medicine and therapies, 2024; 24(1): 250.
BRAZEAU D, et al. Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomized, placebo-controlled, clinical trial protocol. BMJ open, 2025; 15(2): e092919.
BOEHNKE KF, et al. Cannabidiol product dosing and decision-making in a national survey of individuals with fibromyalgia. The journal of pain: official journal of the American Pain Society, 2022; 23(1): 45–54.
CUNNINGHAM CO, et al. Medical Marijuana and Opioids (MEMO) Study: protocol of a longitudinal cohort study to examine if medical cannabis reduces opioid use among adults with chronic pain. BMJ open, 2020; 10(12): e043400.
GIANGREGORIO A, et al. Predictors of response to medical cannabis for chronic pain: A retrospective review of real-time observational data. Cannabis (Research Society on Marijuana), 2024; 7(3): 167–176.
HALL N, et al. Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain. Journal of cannabis research, 2023; 5(1): 11.
HOCH E, et al. Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European archives of psychiatry and clinical neuroscience, 2025; 275(2): 281–292.
HUANG A, et al. A survey on the use of cannabidiol (CBD) isolate, its perceived benefits, and associated side effects among subjects with chronic pain. Cureus, 2025; 17(3): e80198.
KAUFMANN R, et al. Long-term, self-dosing CBD users: Indications, dosage, and self-perceptions on general health/symptoms and drug use. Medical cannabis and cannabinoids, 2023; 6(1): 77–88.
LENT MR, et al. Clinical and psychosocial changes in adults with opioid use disorder and chronic pain using medical cannabis: a brief report. Journal of cannabis research, 2025; 7(1): 36.
MANCA A, et al. Cannabinoid levels description in a cohort of patients with chronic and neuropathic pain treated with Cannabis decoction: A possible role of TDM. Biomedecine & pharmacotherapie, 2024; 175(116686): 116686.
MORENO-SANZ G, et al. Sex-dependent prescription patterns and clinical outcomes associated with the use of two oral cannabis formulations in the multimodal management of chronic pain patients in Colombia. Frontiers in pain research (Lausanne, Switzerland), 2022; 3: e854795.
NUTT DJ, et al. A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products. Cannabis and cannabinoid research, 2022; 7(4): 482–500.
PIKE CK, et al. Study protocol for a phase II, double-blind, randomized controlled trial of cannabidiol (CBD) compared with placebo for reduction of brain neuroinflammation in adults with chronic low back pain. BMJ open, 2022; 12(9): e063613.
PRAMHAS S, et al. Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. The Lancet regional health. Europe, 2023; 35(100777): 100777.
PUD D, et al. Cannabis oil extracts for chronic pain: what else can be learned from another structured prospective cohort? Pain reports (Baltimore, Md.), 2024; 9(2): e1143.
SOLMI M, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomized controlled trials and observational studies. BMJ (Clinical research ed.), 2023; 382: e072348.
VILLANUEVA MRB, et al. Efficacy, safety, and regulation of cannabidiol on chronic pain: A Systematic Review. Cureus, 2022; 14(7): e26913.
WILLIAMS AR, et al. Adult medical cannabinoid use and changes in prescription controlled substance use. Cannabis and cannabinoid research, 2023; 8(5): 933–941.